Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating β-catenin signaling

Cancer Research

Volumn 68, Issue 13, 2008, Pages 5086-5095

  Pai, Rama ^a   Dunlap, Debra ^a   Qing, Jing ^a   Mohtashemi, Iman ^a   Hotzel, Kathy ^a   French, Dorothy M ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CASPASE 3; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 19; GLYCOGEN SYNTHASE KINASE 3; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; UVOMORULIN; ANTIBODY; FGF19 PROTEIN, HUMAN; FGFR4 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLYCOGEN SYNTHASE KINASE 3 BETA; PROTEIN TYROSINE KINASE; SERINE; SMALL INTERFERING RNA; THREONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; COLON CANCER; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR XENOGRAFT; UBIQUITINATION; ANIMAL; CELL CULTURE; CELL PROLIFERATION; CELL STRAIN HCT116; CHEMISTRY; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVE SITE; GENETICS; IMMUNOLOGY; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES; BETA CATENIN; CATALYTIC DOMAIN; CELL PROLIFERATION; COLONIC NEOPLASMS; FEMALE; FIBROBLAST GROWTH FACTORS; GLYCOGEN SYNTHASE KINASE 3; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RNA, SMALL INTERFERING; SERINE; SIGNAL TRANSDUCTION; THREONINE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 48549092215     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2325     Document Type: Article

References (50)

1. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2:REVIEWS3005.
2. Xie MH, Holcomb I, Deuel B, et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999;11:729-35.
3. Nicholes K, Guillet S, Tomlinson E, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002;160:2295-307.
4. Katoh M, Katoh M. Cross-talk of WNT and FGF signaling pathways at GSK3b to regulate β-catenin and SNAIL signaling cascades. Cancer Biol Ther 2006;5:1059-64.
5. Lilien J, Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of β-catenin. Curr Opin Cell Biol 2005;17:459-65.
6. Nelson WJ, Nusse R. Convergence of Wnt, β-catenin, and cadherin pathways. Science 2004;303:1483-7.
7. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
8. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science 2000;287:1606-9.
9. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006;127:469-80.
10. Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3 b by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 1993;296:15-9.
11. Stambolic V, Woodgett JR. Mitogen inactivation of glycogen synthase kinase-3b in intact cells via serine 9 phosphorylation. Biochem J 1994;303:701-4.
12. Cross DA, Alessi DR, Vandenheede JR, et al. The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. Biochem J 1994;303:21-6.
13. Morin PJ. β-catenin signaling and cancer. Bioessays 1999;21:1021-30.
14. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
15. Rubinfeld B, Albert I, Porfiri E, et al. Binding of GSK3b to the APC-β-catenin complex and regulation of complex assembly. Science 1996;272:1023-6.
16. Jaakkola S, Salmikangas P, Nylund S, et al. Amplification of FGFR4 gene in human breast and gynecological cancers. Int J Cancer 1993;54:378-82.
17. Jeffers M, LaRochelle WJ, Lichenstein HS. Fibroblast growth factors in cancer: therapeutic possibilities. Expert Opin Ther Targets 2002;6:469-82.
18. Gowardhan B, Douglas DA, Mathers ME, et al. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005;92:320-7.
19. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 2002;109:69-78.
20. Bange J, Prechtl D, Cheburkin Y, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002;62:840-7.
21. Streit S, Bange J, Fichtner A, et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 2004;111:213-7.
22. Spinola M, Leoni V, Pignatiello C, et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 2005;23:7307-11.
23. Chan TA, Wang Z, Dang LH, Vogelstein B, Kinzler KW. Targeted inactivation of CTNNB1 reveals unexpected effects of β-catenin mutation. Proc Natl Acad Sci U S A 2002;99:8265-70.
24. Desnoyers LR, Pai R, Ferrando RE, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008;27:85-97.
25. Porfiri E, Rubinfeld B, Albert I, et al. Induction of a β-catenin-LEF-1 complex by wnt-1 and transforming mutants of β-catenin. Oncogene 1997;15:2833-9.
26. Lin BC, Wang M, Blackmore C, Desnoyers LR. Liver-specific activities of FGF19 require Klotho β. J Biol Chem 2007;282:27277-84.
27. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006;1:2315-9.
28. Staal FJ, Noort Mv M, Strous GJ, Clevers HC. Wnt signals are transmitted through N-terminally dephosphorylated β-catenin. EMBO Rep 2002;3:63-8.
29. Polakis P. Casein kinase 1: a Wnt'er of disconnect. Curr Biol 2002;12:R499-501.
30. Jamora C, Fuchs E. Intercellular adhesion, signalling and the cytoskeleton. Nat Cell Biol 2002;4:E101-8.
31. Gumbiner BM. Regulation of cadherin adhesive activity. J Cell Biol 2000;148:399-404.
32. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993;5:806-11.
33. Ezzat S, Zheng L, Winer D, Asa SL. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications. Mol Endocrinol 2006;20:2965-75.
34. El-Hariry I, Pignatelli M, Lemoine NR. FGF-1 and FGF-2 regulate the expression of E-cadherin and catenins in pancreatic adenocarcinoma. Int J Cancer 2001;94:652-61.
35. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16:3797-804.
36. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW. Serine phosphorylation-regulated ubiquitination and degradation of β-catenin. J Biol Chem 1997;272:24735-8.
37. Liu C, Li Y, Semenov M, et al. Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002;108:837-47.
38. Amit S, Hatzubai A, Birman Y, et al. Axin-mediated CKI phosphorylation of β-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev 2002;16:1066-76.
39. Yanagawa S, Matsuda Y, Lee JS, et al. Casein kinase I phosphorylates the Armadillo protein and induces its degradation in Drosophila. EMBO J 2002;21:1733-42.
40. Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-TCF signaling in colon cancer by mutations in β-catenin or APC. Science 1997;275:1787-90.
41. Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, Bodmer WF. β-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A 1997;94:10330-4.
42. Bordonaro M, Lazarova DL, Sartorelli AC. The activation of β-catenin by Wnt signaling mediates the effects of histone deacetylase inhibitors. Exp Cell Res 2007;313:1652-66.
43. Wang Z, Vogelstein B, Kinzler KW. Phosphorylation of β-catenin at S33, S37, or T41 can occur in the absence of phosphorylation at T45 in colon cancer cells. Cancer Res 2003;63:5234-5.
44. Behrens J. Cross-regulation of the Wnt signalling pathway: a role of MAP kinases. J Cell Sci 2000;113:911-9.
45. Ding Q, Xia W, Liu JC, et al. Erk associates with and primes GSK-3b for its inactivation resulting in upregulation of β-catenin. Mol Cell 2005;19:159-70.
46. Shimokawa T, Furukawa Y, Sakai M, et al. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the β-catenin/T-cell factor complex. Cancer Res 2003;63:6116-20.
47. Chamorro MN, Schwartz DR, Vonica A, et al. FGF-20 and DKK1 are transcriptional targets of β-catenin and FGF-20 is implicated in cancer and development. EMBO J 2005;24:73-84.
48. Billottet C, Elkhatib N, Thiery JP, Jouanneau J. Targets of fibroblast growth factor 1 (FGF-1) and FGF-2 signaling involved in the invasive and tumorigenic behavior of carcinoma cells. Mol Biol Cell 2004;15:4725-34.
49. Holnthoner W, Pillinger M, Groger M, et al. Fibroblast growth factor-2 induces Lef/TCF-dependent transcription in human endothelial cells. J Biol Chem 2002;277:45847-53.
50. Ciruna B, Rossant J. FGF signaling regulates mesoderm cell fate specification and morphogenetic movement at the primitive streak. Dev Cell 2001;1:37-49.